Grzegorz S. Nowakowski, MD, consultant, Division of Hematology; enterprise deputy director, Clinical Research, Mayo Clinic Comprehensive Cancer Center, discusses the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), emphasizing the need for novel therapeutic approaches to treat patients in the second-line setting.
Standard frontline therapy for DLBCL typically involves chemoimmunotherapy regimens, such as R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone), which has been associated with an overall response rate of approximately 80% to 90%, Nowakowski explains, adding that approximately 60% to 70% of patients can achieve complete remission. Despite these high initial response rates, a proportion of patients will still experience disease relapse, including many within the first 2 years of initiating treatment. For the approximately 40% of patients with DLBCL who experienced relapse following frontline chemoimmunotherapy, the prognosis is often poor with limited long-term survival, Nowakowski explains.
Негізгі бет Dr Nowakowski on the Current Treatment Landscape for DLBCL
Пікірлер